| Literature DB >> 29947692 |
Letícia Biscaino Alves1,2, Maria Teresa Tsukazan3, Ana Elisa Serafim3, Rolando Mendoza3, Alexandre Vontobel Padoin2,4, Plínio Carlos Baú5, Luis Fernando Moreira1.
Abstract
BACKGROUND: The carcinoembryonic antigen level in peritoneal lavage has been showing to be a reliable prognostic factor in gastric cancer. AIM: To identify any association between carcinoembryonic antigen level in peritoneal lavage, in gastric cancer patients, with mortality, peritoneal recurrence, tumor relapse or other prognostic factors.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29947692 PMCID: PMC6049989 DOI: 10.1590/0102-672020180001e1358
Source DB: PubMed Journal: Arq Bras Cir Dig ISSN: 0102-6720
Tumor characteristics of patients with gastric cancer (n=30)
| Characteristics | n (%) |
| Serosa invasion (T3 ouT4) | 25 (83.3) |
| Lymph node’s involvement (N1-3) | 20 (66.7) |
| Distance metastasis (M1) | 7 (23.3) |
| Clinical stage IV | 12 (40) |
| Positive cytology | 2 (6.7) |
| Positive plCEA | 10 (33.33) |
Recurrence in patients with gastric cancer
| Recurrence | n (%) |
| Recurrence in six months | 7 (23.3) |
| Total recurrence | 11 (36.7) |
| Peritoneal recurrence | 7 (23.3) |
| Recurrence or gastric cancer progression | 14 (46.7) |
Factors related to elevated plCEA
| Factors | Statistical significance |
| Positive cytology | p=0.038 |
| Involvement of lymph nodes | p=0.006 |
| T4 stage | p=0.015 |
| IV SG | p=0.002 |
Factors related to recurrence or disease progression
| Factors | Univariate analysis | Logistic regression |
| plCEA | OR: 27 (2.705 - 269.460)95 IC | OR: 38.206 (1.075 - 1358.419)95 IC NS* NS* |
| Lymph nodes involvement | OR: 16.714 (1.742 - 160.350)95 IC | |
| T4 stage | OR: 11.25 (1.146 - 110.461)95 IC | |
| Distant metastases | OR: 11,25 (1,146 - 110,461)95 IC | NS* |
| IV stage grouping | OR: 17.5 (2.667 - 114.846)95 IC | NS* |
| Residual disease | RR: 1.4 (1.005 - 1.950)95 IC | NS* |
| Extended lymphadenectomy not performed | OR: 5.4 (1.120 - 26.044)95 IC | NS* |
| Adjuvant therapy not performed | OR: 6 (1.003 - 35.908)95 IC | NS* |
*Not significant
Factors related to mortality
| Mortality in six months | General mortality | |||
| Factors | Univariate analysis | Logistic regression | Univariate analysis | Logistic regression |
| plCEA | OR: 8.5 (1.458 - 49.539)IC 95% | NS* | RR: 2.111 (1.314 - 3.391)IC 95% | NS* |
| Residual disease | RR: 1.8 (1.003 - 3.229)IC 95% | NS* | NS* | NA** |
| Lymph node involvement | NS* | NA** | OR: 9.333 (1.637 - 53.208)IC 95% | NS* |
| Stage T4 | NS* | NA** | RR: 1.583 (1.123 - 2.232)IC 95% | NS* |
| IV SG | NS* | NA** | RR: 2.714 (1.507 - 4.890)IC 95% | NS* |
| Distant metastases | NS* | NA** | RR: 1.583 (1.123 - 2.232)IC 95% | NS* |
| Extended lymphadenectomy | NS* | NA** | OR: 6.188 (1.041 - 36.779)IC 95% | NS* |
| Lack of adjuvant therapy | RR: 1.818 (1.223 - 2.703)IC 95% | NS* | OR: 22.667 (3.140 - 163.629)IC 95% | NS* |
*No significance **Not available
FIGURE 1Overall survival